Adding crizotinib to radiotherapy may help preserve hearing in patients with neurofibromatosis 2

Adding the targeted cancer therapy drug crizotinib to radiotherapy for tumours associated with the genetic disorder neurofibromatosis 2 may reduce the hearing damage that can be exacerbated by radiotherapy.
EurekAlert